GlassScriptPhysician profile
Scott B Baron
NPI 1215038930
$230,680.58
in general payments reported to CMS, 2019-2025
44 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $6,742 · 2021: $7,182 · 2022: $64K · 2023: $74K · 2024: $20K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $78K · Travel and Lodging: $15K · Honoraria: $7,560 · Food and Beverage: $4,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,695.00 |
| Travel and Lodging | $15,144.91 |
| Honoraria | $7,560.00 |
| Food and Beverage | $4,776.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $128,360.46 | 2021-2024 | Verquvo |
| Amgen INC. | $39,579.67 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $13,787.72 | 2019-2022 | |
| Pfizer INC. | $12,759.88 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $9,174.20 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $6,126.08 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $5,865.42 | 2019-2023 | Mitraclip |
| Astrazeneca Pharmaceuticals LP | $4,122.25 | 2019-2023 | Farxiga |
| Medtronic, INC. | $2,502.11 | 2021-2025 | Ffrangio, Telescope, Symplicity G3 |
| Sanofi-Aventis U.S. LLC | $2,195.21 | 2019-2022 | |
| Medtronic Vascular, INC. | $1,525.95 | 2019-2020 | |
| Boston Scientific Corporation | $597.26 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $509.77 | 2019-2022 | |
| Abiomed | $358.03 | 2020-2023 | Impella |
| Inari Medical, INC. | $324.32 | 2020-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.